MyMD Pharmaceuticals, Inc. (MYMD)
$2.34
+0.17 (+7.83%)
Rating:
Recommendation:
-
| Symbol | MYMD |
|---|---|
| Price | $2.34 |
| Beta | 0.287 |
| Volume Avg. | 0.06M |
| Market Cap | 89.056M |
| Shares () | - |
| 52 Week Range | 1.88-9.95 |
| 1y Target Est | - |
| DCF Unlevered | MYMD DCF -> | |
|---|---|---|
| DCF Levered | MYMD LDCF -> | |
| ROE | -119285.73% | Strong Sell |
| ROA | -134625.86% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 13.16% | Neutral |
| P/E | - | |
| P/B | 4.55 | Strong Buy |
Latest MYMD news
About
Download (Excel)MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.